Andrew H. Lane is President & VP at ABBOTT LABORATORIES (ABT). They have made 5 open-market trades across 1 company since 2018, most recently 2021-11-15.
CIK 0001643735
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ABT | 76,087 | $8.8M |
Shares reported on the most recent Form 4, priced at the 2021-11-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ABT | SELL | 2021-11-15 | 2021-11-17 | $130.01 | $1.3M | -2.7% | +6.0% | -4.1% |
| ABT | SELL | 2021-08-27 | 2021-08-31 | $125.48 | $17.1M | +0.7% | -6.0% | +1.8% |
| ABT | SELL | 2020-05-05 | 2020-05-07 | $92.00 | $7.4M | -7.0% | -2.4% | +7.7% |
| ABT | SELL | 2019-06-12 | 2019-06-14 | $81.42 | $12.0M | +0.7% | +1.7% | +3.4% |
| ABT | SELL | 2018-08-29 | 2018-08-31 | $67.11 | $1.2M | +2.6% | +11.1% | +9.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.